SCND: Scientific Industries, Inc. Stock

by  •  • Comments Off on SCND: Scientific Industries, Inc. Stock

SIC 3826 – Laboratory Analytical Instruments

Valuation
Market Cap ($M) 15.13
Enterprise Value ($M) 14.54
Book Value ($M) 9.12
Book Value / Share 0.87
Price / Book 1.66
NCAV ($M) 5.85
NCAV / Share 0.56
Price / NCAV 2.59

Profitability (mra)
Return on Invested Capital (ROIC) -0.64
Return on Assets (ROA) -0.41
Return on Equity (ROE) -0.51

Liquidity (mrq)
Quick Ratio 2.41
Current Ratio 4.74

Balance Sheet (mrq) ($M)
Current Assets 8.29
Assets 11.56
Liabilities 2.44
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 10.71
Operating Income -6.64
Net Income -6.45
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -3.68
Cash from Investing 2.87
Cash from Financing 0.65

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-23 13D/A Pessin Sandra F 3.90 10.80
04-22 13D/A Bleichroeder LP 22.69 20.28
02-13 13G/A North Run Capital, Lp 9.99 -1.11
02-12 13G/A Satterfield Thomas A Jr 9.90 20.35
11-14 13G/A Lytton Laurence W 9.99 -1.47

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SE
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION
2024-07-18 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PUR
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTIO

(click for more detail)

Similar Companies
PBIO – Pressure BioSciences, Inc. QURT – Quarta-Rad, Inc.
RSCF – Reflect Scientific, Inc. SDMHF – Sartorius Stedim Biotech S.A.
SIEVF – D'Ieteren Group SA


Financial data and stock pages provided by
Fintel.io